A strategic framework has been devised with nine priority actions to enhance quality, accessibility, innovation and sustainability in trials.

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.

XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.

According to the World Health Organization, autism spectrum disorder (ASD) affects approximately 10% of children globally. ASD is theorised to be caused by a combination of genetic and environmental ...

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

The US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index (BMI) in all three doses.

US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.

A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.

Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around data quality.